News & Updates

CheckMate 040: Nivolumab, cabozantinib ± ipilimumab improves outcomes in aHCC

03 Mar 2020 by

The combination therapy of nivolumab (NIVO) and cabozantinib (CABO) with or without ipilimumab (IPI) demonstrates activity in advanced hepatocellular carcinoma (aHCC), according to the CheckMate 040* study presented at ASCO GI 2020.

CheckMate 040: Nivolumab, cabozantinib ± ipilimumab improves outcomes in aHCC

03 Mar 2020

HCV clearance may improve glucose metabolism

24 Feb 2020

Abnormal glycometabolism is more common among patients with hepatitis C virus (HCV) infection, and viral clearance may improve glucose control, a recent study has found.

HCV clearance may improve glucose metabolism

24 Feb 2020

Liver stiffness linked to HCC survival, recurrence after ablation

19 Feb 2020

Liver stiffness (LS) may predict the recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA), a recent study has found. Spleen stiffness (SS), on the other hand, may precede hepatic decompensation.

Liver stiffness linked to HCC survival, recurrence after ablation

19 Feb 2020

Tenofovir on par with entecavir for HCC prevention in CHB patients

17 Feb 2020

No significant difference is seen between entecavir and tenofovir disoproxil fumarate (TDF) in terms of their effectiveness for preventing hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB), according to a recent study.

Tenofovir on par with entecavir for HCC prevention in CHB patients

17 Feb 2020

High fructose intake not linked to negative metabolic effects in healthy individuals

10 Feb 2020

Prolonged ingestion of a high-dose dietary fructose does not result in relevant metabolic consequences in the presence of a stable energy intake, slightly lower body weight and potentially incomplete absorption of orally administered fructose load, according to a study.

High fructose intake not linked to negative metabolic effects in healthy individuals

10 Feb 2020

NAFLD ups risk of coronary artery calcification

08 Feb 2020

The risk of coronary artery calcification (CAC) is elevated among nonobese men with nonalcoholic fatty liver disease (NAFLD), a recent study has found.

NAFLD ups risk of coronary artery calcification

08 Feb 2020

Transarterial chemoembolization plus sorafenib improves survival in unresectable HCC

08 Feb 2020

Performing transarterial chemoembolization (TACE) in addition to sorafenib therapy yields a significant increase in progression-free survival in patients with unresectable hepatocellular carcinoma (HCC) when compared with TACE alone, according to the results of the TACTICS* trial.

Transarterial chemoembolization plus sorafenib improves survival in unresectable HCC

08 Feb 2020

Atezolizumab-bevacizumab combo maintains QoL in liver cancer patients

07 Feb 2020 by

The combination of the PD-L1* inhibitor atezolizumab and the VEGF** inhibitor bevacizumab generated substantial and consistent benefits in terms of quality of life (QoL) compared with standard-of-care sorafenib in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, according to the patient-reported outcomes (PROs) from the IMbrave150*** trial presented at ASCO GI 2020.

Atezolizumab-bevacizumab combo maintains QoL in liver cancer patients

07 Feb 2020

Belapectin benefits cirrhotic NASH patients without oesophageal varices

05 Feb 2020 by

A 12-month course of biweekly infusion of belapectin is safe and induces significant reductions in hepatic venous pressure gradient (HVPG) or fibrosis, in addition to preventing the development of varices, in the subgroup of nonalcoholic steatohepatitis (NASH) patients with cirrhosis but without oesophageal varices, as shown in the results of a phase IIb study.

Belapectin benefits cirrhotic NASH patients without oesophageal varices

05 Feb 2020

NAFLD risk, remission influenced by lifestyle

29 Jan 2020

Lifestyle factors, such as weight gain, smoking and exercise, appear to affect the development and remission of nonalcoholic fatty liver disease (NAFLD), reports a recent study.

NAFLD risk, remission influenced by lifestyle

29 Jan 2020

News & Updates

Filter by Specialty:

Specialty:

CheckMate 040: Nivolumab, cabozantinib ± ipilimumab improves outcomes in aHCC

CheckMate 040: Nivolumab, cabozantinib ± ipilimumab improves outcomes in aHCC

HCV clearance may improve glucose metabolism

HCV clearance may improve glucose metabolism

Liver stiffness linked to HCC survival, recurrence after ablation

Liver stiffness linked to HCC survival, recurrence after ablation

Tenofovir on par with entecavir for HCC prevention in CHB patients

Tenofovir on par with entecavir for HCC prevention in CHB patients

High fructose intake not linked to negative metabolic effects in healthy individuals

High fructose intake not linked to negative metabolic effects in healthy individuals

NAFLD ups risk of coronary artery calcification

NAFLD ups risk of coronary artery calcification

Transarterial chemoembolization plus sorafenib improves survival in unresectable HCC

Transarterial chemoembolization plus sorafenib improves survival in unresectable HCC

Atezolizumab-bevacizumab combo maintains QoL in liver cancer patients

Atezolizumab-bevacizumab combo maintains QoL in liver cancer patients

Belapectin benefits cirrhotic NASH patients without oesophageal varices

Belapectin benefits cirrhotic NASH patients without oesophageal varices

NAFLD risk, remission influenced by lifestyle

NAFLD risk, remission influenced by lifestyle